Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India Physician Conduct Rules Want Them Off Pharma-Sponsored Symposia

Executive Summary

Wider-ranging new draft rules suggest that physicians in India should not engage in educational activity sponsored by pharma and urges them to declare financial earnings and benefits received from industry via an affidavit. The Pink Sheet discusses with industry experts some of the nuances and seeming loopholes in the rules, currently in self-regulatory mode but with penalties proposed for violation.

You may also be interested in...



AdvaMed Launches Ethics Code To Meet ‘Business And Market Realities’ In India

Industry group AdvaMed says its Indian code on interactions between medtech companies and health care professionals is a first for the country.

What’s Next At Dr Reddy’s: Biologics CDMO, Cell And Gene Therapy Push

Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.

Afrigen MD: WTO IP Waiver Important From ‘Freedom To Operate’ Standpoint

Afrigen’s MD, Petro Terblanche, discusses the operational freedom that the WTO intellectual property waiver provides for its COVID-19 vaccine being developed under the wider WHO-backed mRNA technology transfer hub initiative. The executive doesn’t anticipate big pharma pushback but says the alliance will “test the system”, though others believe the waiver in its current form doesn’t count for much.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS146277

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel